Orgovyx (Relugolix): The 2029-2037 Generic Opportunity Window

Orgovyx (relugolix, 120 mg oral tablets, NDA 214621) is Sumitomo Pharma and Pfizer's first-in-class oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. FDA for the treatment of adult patients with advanced prostate cancer. By competitively binding pituitary GnRH receptors, relugolix rapidly depletes luteinizing hormone and reduces testosterone to castrate levels without inducing the initial clinical flare typical of injectable peptide GnRH agonists like leuprolide. Orgovyx achieved over $300 million in U.S. net revenues in 2024 and expanded toward $400M-$500M in 2025-2026, steadily capturing market share in outpatient urology. Orgovyx's Orange Book patent fortress establishes a multi-tiered generic opportunity window: 1. Core Drug Substance: U.S. Patent No. 7,300,935 expires on January 28, 2029 (including Patent Term Extension under 35 U.S.C. 156), claiming the relugolix uracil chemical entity. 2. Drug Product Formulation: U.S. Patent No. 10,350,170 protects the commercial solid oral preparation through February 25, 2036. 3. Method of Treatment: U.S. Patent Nos. 10,449,191, 10,786,501, 11,583,526, and 12,097,198 extend theoretical exclusivity through September 29, 2037 for methods of treating prostate cancer. Commercial generic status: 100% brand-only in the United States today; zero generic relugolix is approved for commercial sale or selling in the U.S. Strong generic manufacturer positioning has emerged: Sandoz has secured FDA Tentative Approval for generic relugolix tablets (ANDA 219913), while Indian generic manufacturers and specialized filers including Aizant Drug Research Solutions (ANDA 220197) and BDR Pharmaceuticals / Apotex have submitted Paragraph IV certifications challenging Orange Book patents. SCOPE NOTE: Active Hatch-Waxman Paragraph IV patent litigation is pending in the U.S. District Court for the District of Delaware concerning whether generic relugolix tablets infringe asserted formulation and method claims or whether those claims are valid. This analysis reports only statutory Orange Book expiration dates, published patent claims, and public regulatory filings, taking no position on pending judicial disputes or unadjudicated infringement contentions.